‘Considerable increase’ in pay-for-delay settlements: FTC report

The number of ‘pay-for-delay’ patent settlements reached in fiscal year (FY) 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission (FTC) report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pay-for-delay settlements fall for second year: FTC report

6 November 2017 Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.

Americas

California outlaws pay-for-delay deals

9 October 2019 California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.

Americas

Number of pay-for-delay deals remains low, says FTC

7 December 2020 The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.